2023 World Conference on Lung Cancer (Posters)-P2.20. Differential Expression of Genes in Type A and B3 Thymomas and Thymic Carcinomas

P2.20. Differential Expression of Genes in Type A and B3 Thymomas and Thymic Carcinomas - PDF(Abstract)

Pdf Summary

This study aimed to identify genes that are differentially expressed in type A and B3 thymomas and thymic carcinomas, as well as gain a better understanding of the pathogenesis of these tumors. The researchers analyzed a database of thymic epithelial tumors (TET) from the Mayo Clinic Rochester and profiled RNA expression using the nCounter Tumor Signaling 360TM Panel. Three R-based methods were used to analyze the data, and a consensus approach was used to compare samples of different TET subtypes (type A and B3 thymomas, thymic carcinomas, and controls). The study population included 19 type A thymomas, 11 type B3 thymomas, and 34 thymic carcinomas. The number of genes that were significantly up- or downregulated in various TET subtypes was summarized. Type A and B3 thymomas and thymic carcinomas were found to harbor genes that are differentially expressed and clinically relevant. A subset of these genes appears to be uniquely differentially expressed by TET subtype, which may be useful in distinguishing these tumor entities. For example, the CHEK2 gene, encoding a tumor suppressor and DNA repair protein, was found to have significantly higher expression in type A thymomas, while JAK3 and CD80, both involved in the immune system and anti-tumoral immune response, displayed higher expression in thymic carcinomas. Further analysis will be performed to correlate gene expression with clinical features, outcome, and available targeted therapies. This research provides valuable insights into the molecular landscape of TET and may contribute to the development of more effective treatment strategies for these tumors.

Asset Subtitle

Anja Roden

Meta Tag

Speaker Anja Roden

Topic Thymic Malignancy

Keywords

genes

differential expression

type A thymomas

B3 thymomas

thymic carcinomas

pathogenesis

tumor signaling

RNA expression

TET subtypes

Mayo Clinic Rochester